HRP20090527T1 - Nogo-a neutralising immunoglobulins for treatment of neurological diseases - Google Patents
Nogo-a neutralising immunoglobulins for treatment of neurological diseasesInfo
- Publication number
- HRP20090527T1 HRP20090527T1 HR20090527T HRP20090527T HRP20090527T1 HR P20090527 T1 HRP20090527 T1 HR P20090527T1 HR 20090527 T HR20090527 T HR 20090527T HR P20090527 T HRP20090527 T HR P20090527T HR P20090527 T1 HRP20090527 T1 HR P20090527T1
- Authority
- HR
- Croatia
- Prior art keywords
- nogo
- neutralising
- immunoglobulins
- treatment
- neurological diseases
- Prior art date
Links
- 108060003951 Immunoglobulin Proteins 0.000 title 1
- 208000012902 Nervous system disease Diseases 0.000 title 1
- 208000025966 Neurological disease Diseases 0.000 title 1
- 102000018358 immunoglobulin Human genes 0.000 title 1
- 229940072221 immunoglobulins Drugs 0.000 title 1
- 230000003472 neutralizing effect Effects 0.000 title 1
- 108010047041 Complementarity Determining Regions Proteins 0.000 abstract 4
- 239000012634 fragment Substances 0.000 abstract 2
- 102000010410 Nogo Proteins Human genes 0.000 abstract 1
- 108010077641 Nogo Proteins Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/70—Enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/998—Proteins not provided for elsewhere
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Pharmacology & Pharmacy (AREA)
- Wood Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0329711A GB0329711D0 (en) | 2003-12-22 | 2003-12-22 | Antibodies |
| GB0329684A GB0329684D0 (en) | 2003-12-22 | 2003-12-22 | Method |
| PCT/GB2004/005325 WO2005061544A2 (en) | 2003-12-22 | 2004-12-20 | Nogo-a neutralising immunoglobulins for treatment of neurological diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20090527T1 true HRP20090527T1 (en) | 2009-11-30 |
Family
ID=34712703
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20090527T HRP20090527T1 (en) | 2003-12-22 | 2009-10-01 | Nogo-a neutralising immunoglobulins for treatment of neurological diseases |
Country Status (28)
| Country | Link |
|---|---|
| US (4) | US7988964B2 (xx) |
| EP (3) | EP1711530B1 (xx) |
| JP (2) | JP2007537145A (xx) |
| KR (1) | KR101150548B1 (xx) |
| AR (1) | AR048912A1 (xx) |
| AT (1) | ATE440866T1 (xx) |
| AU (1) | AU2004303585B2 (xx) |
| BR (1) | BRPI0417959A (xx) |
| CA (1) | CA2549956C (xx) |
| CY (1) | CY1110530T1 (xx) |
| DE (1) | DE602004022871D1 (xx) |
| DK (1) | DK1711530T3 (xx) |
| ES (1) | ES2330444T3 (xx) |
| HK (1) | HK1100144A1 (xx) |
| HR (1) | HRP20090527T1 (xx) |
| IL (1) | IL176206A (xx) |
| IS (1) | IS2739B (xx) |
| MA (1) | MA28289A1 (xx) |
| MX (1) | MXPA06007190A (xx) |
| MY (1) | MY144612A (xx) |
| NO (1) | NO20062767L (xx) |
| NZ (1) | NZ548013A (xx) |
| PL (1) | PL1711530T3 (xx) |
| PT (1) | PT1711530E (xx) |
| RU (1) | RU2362780C2 (xx) |
| SI (1) | SI1711530T1 (xx) |
| TW (1) | TWI329649B (xx) |
| WO (2) | WO2005061544A2 (xx) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1355666B1 (en) | 2000-12-22 | 2012-06-13 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Use of repulsive guidance molecule (RGM) and its modulators |
| GB0228832D0 (en) * | 2002-12-10 | 2003-01-15 | Novartis Ag | Organic compound |
| DE10303974A1 (de) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
| GB0321997D0 (en) * | 2003-09-19 | 2003-10-22 | Novartis Ag | Organic compound |
| PL1711530T3 (pl) | 2003-12-22 | 2010-01-29 | Glaxo Group Ltd | Immunoglobuliny neutralizujące Nogo-A do leczenia chorób neurologicznych |
| AU2006265276B2 (en) * | 2005-07-05 | 2011-10-13 | Glaxo Group Limited | Humanised antibodies specific for NOGO-A and pharmaceutical uses thereof |
| CA2624562A1 (en) | 2005-09-30 | 2007-04-12 | Abbott Gmbh & Co. Kg | Binding domains of proteins of the repulsive guidance molecule (rgm) protein family and functional fragments thereof, and their use |
| CN117903302A (zh) | 2005-11-30 | 2024-04-19 | Abbvie 公司 | 抗-Aβ球聚体抗体，其相关产品，生产所述抗体的方法，所述抗体的应用以及使用方法 |
| PL1976877T5 (pl) | 2005-11-30 | 2017-09-29 | Abbvie Inc | Przeciwciała monoklonalne przeciwko białku amyloidu beta oraz ich zastosowania |
| GB0525662D0 (en) * | 2005-12-16 | 2006-01-25 | Glaxo Group Ltd | Immunoglobulins |
| US8663635B2 (en) | 2006-03-21 | 2014-03-04 | The Regents Of The University Of California | N-cadherin: target for cancer diagnosis and therapy |
| WO2008002594A2 (en) * | 2006-06-27 | 2008-01-03 | Neuroprotection For Life Corp. | Neuronal circuit-dependent neuroprotection by interaction between nicotinic receptors |
| US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
| CA2672120A1 (en) * | 2006-12-07 | 2008-06-12 | Novartis Ag | Antagonistic antibodies against ephb3 |
| EP2486928A1 (en) * | 2007-02-27 | 2012-08-15 | Abbott GmbH & Co. KG | Method for the treatment of amyloidoses |
| WO2009026117A2 (en) * | 2007-08-16 | 2009-02-26 | Glaxo Group Limited | Novel compounds |
| AU2008317724B2 (en) | 2007-11-02 | 2011-06-02 | Novartis Ag | Improved Nogo-A binding molecules and pharmaceutical use thereof |
| US8962803B2 (en) * | 2008-02-29 | 2015-02-24 | AbbVie Deutschland GmbH & Co. KG | Antibodies against the RGM A protein and uses thereof |
| KR20100132998A (ko) * | 2008-04-04 | 2010-12-20 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 종양 성장, 혈관신생 및 전이를 차단하는 것을 목표로 하는 암에 대한 항체 |
| CA2730473A1 (en) * | 2008-07-11 | 2010-01-14 | Glaxo Group Limited | Novel treatment |
| US10266585B2 (en) | 2009-08-28 | 2019-04-23 | The Board Of Regents Of The Univerity Of Texas System | Methods of treating brain injury |
| US9175075B2 (en) | 2009-12-08 | 2015-11-03 | AbbVie Deutschland GmbH & Co. KG | Methods of treating retinal nerve fiber layer degeneration with monoclonal antibodies against a retinal guidance molecule (RGM) protein |
| CA2796339C (en) | 2010-04-15 | 2020-03-31 | Abbott Laboratories | Amyloid-beta binding proteins |
| US8828390B2 (en) | 2010-07-09 | 2014-09-09 | Universitat Zurich | Uses of NOGO-A inhibitors and related methods |
| CA2808187A1 (en) | 2010-08-14 | 2012-02-23 | Abbvie Inc. | Amyloid-beta binding proteins |
| AU2011315920B2 (en) * | 2010-10-15 | 2016-04-28 | The Board Of Regents Of The University Of Texas System | Antibodies that bind amyloid oligomers |
| WO2012058592A2 (en) | 2010-10-29 | 2012-05-03 | Immunogen, Inc. | Non-antagonistic egfr-binding molecules and immunoconjugates thereof |
| WO2012058588A2 (en) | 2010-10-29 | 2012-05-03 | Immunogen, Inc. | Novel egfr-binding molecules and immunoconjugates thereof |
| SG11201402343SA (en) | 2011-11-21 | 2014-06-27 | Immunogen Inc | Method of treatment of tumors that are resistant to egfr therapies by egfr antibody cytotoxic agent conjugate |
| CA2863224A1 (en) | 2012-01-09 | 2013-07-18 | The Scripps Research Institute | Ultralong complementarity determining regions and uses thereof |
| SG10202006762PA (en) | 2012-01-27 | 2020-08-28 | Abbvie Deutschland | Composition and method for diagnosis and treatment of diseases associated with neurite degeneration |
| BR112014032987A2 (pt) | 2012-07-05 | 2017-06-27 | Glaxo Group Ltd | método de tratamento ou profilaxia de um distúrbio neurológico |
| PT3292150T (pt) | 2015-05-04 | 2020-06-01 | Cytomx Therapeutics Inc | Anticorpos anti-cd166 ativáveis e os seus métodos de utilização |
| US20180362660A1 (en) * | 2016-05-09 | 2018-12-20 | Schickwann Tsai | Anti-penumbra monoclonal antibodies for detection and therapy of normal and abnormal B lymphocytes |
| EP3652210A1 (en) * | 2017-07-14 | 2020-05-20 | CytomX Therapeutics, Inc. | Anti-cd166 antibodies and uses thereof |
| WO2020068058A1 (en) * | 2018-09-25 | 2020-04-02 | Academia Sinica | Anti-siglec antibody, pharmaceutical composition comprising the same, and uses thereof |
| EP4048692A2 (en) | 2019-10-24 | 2022-08-31 | NovaGo Therapeutics AG | Novel anti-nogo-a antibodies |
| CN116635718A (zh) * | 2020-12-02 | 2023-08-22 | 安捷伦科技有限公司 | 用于在免疫组织化学（ihc）方案中使用以诊断癌症的抗人cd10抗体 |
| WO2024041450A1 (zh) * | 2022-08-22 | 2024-02-29 | 舒泰神（北京）生物制药股份有限公司 | 特异性识别Nogo-A的抗体及其应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3935074A (en) * | 1973-12-17 | 1976-01-27 | Syva Company | Antibody steric hindrance immunoassay with two antibodies |
| HU226535B1 (en) | 1994-05-27 | 2009-03-30 | Glaxosmithkline Spa | Quinoline derivatives as tachykinin nk3 receptor antagonists, pharmaceutical compositions containing them, and their use |
| AU774367C (en) * | 1998-11-06 | 2005-04-21 | University Of Zurich | Nucleotide and protein sequences of nogo genes and methods based thereon |
| FR2792199B3 (fr) | 1999-04-13 | 2001-05-18 | Sanofi Sa | Utilisation de l'osanetant pour la preparation de medicaments utiles dans le traitement des troubles de l'humeur |
| US20030113891A1 (en) * | 2000-02-11 | 2003-06-19 | Lawrence Blatt | Method and reagent for the inhibition of NOGO and NOGO receptor genes |
| GB0101313D0 (en) * | 2001-01-18 | 2001-02-28 | Glaxo Group Ltd | Assay |
| CA2482589A1 (en) * | 2002-04-17 | 2003-10-30 | Pharmacia & Upjohn Company Llc | Compositions and method of treating alzheimer's disease |
| GB0228832D0 (en) * | 2002-12-10 | 2003-01-15 | Novartis Ag | Organic compound |
| JP2006523708A (ja) * | 2003-04-16 | 2006-10-19 | イェール ユニバーシティ | アミロイド斑に関連する状態の処置のためのＮｏｇｏレセプターアンタゴニスト |
| GB0318727D0 (en) | 2003-08-08 | 2003-09-10 | Smithkline Beecham Corp | Novel compounds |
| GB0321997D0 (en) * | 2003-09-19 | 2003-10-22 | Novartis Ag | Organic compound |
| PL1711530T3 (pl) | 2003-12-22 | 2010-01-29 | Glaxo Group Ltd | Immunoglobuliny neutralizujące Nogo-A do leczenia chorób neurologicznych |
-
2004
- 2004-12-20 PL PL04806128T patent/PL1711530T3/pl unknown
- 2004-12-20 EP EP04806128A patent/EP1711530B1/en active Active
- 2004-12-20 AT AT04806128T patent/ATE440866T1/de active
- 2004-12-20 TW TW093139709A patent/TWI329649B/zh not_active IP Right Cessation
- 2004-12-20 MX MXPA06007190A patent/MXPA06007190A/es active IP Right Grant
- 2004-12-20 DK DK04806128T patent/DK1711530T3/da active
- 2004-12-20 EP EP04806145A patent/EP1706426A2/en not_active Withdrawn
- 2004-12-20 US US10/583,877 patent/US7988964B2/en not_active Expired - Fee Related
- 2004-12-20 MY MYPI20045254A patent/MY144612A/en unknown
- 2004-12-20 AR ARP040104811A patent/AR048912A1/es not_active Application Discontinuation
- 2004-12-20 RU RU2006123481/13A patent/RU2362780C2/ru not_active IP Right Cessation
- 2004-12-20 ES ES04806128T patent/ES2330444T3/es active Active
- 2004-12-20 JP JP2006546307A patent/JP2007537145A/ja active Pending
- 2004-12-20 DE DE602004022871T patent/DE602004022871D1/de active Active
- 2004-12-20 BR BRPI0417959-5A patent/BRPI0417959A/pt not_active IP Right Cessation
- 2004-12-20 CA CA2549956A patent/CA2549956C/en not_active Expired - Fee Related
- 2004-12-20 SI SI200431272T patent/SI1711530T1/sl unknown
- 2004-12-20 EP EP09168234A patent/EP2213684A3/en not_active Withdrawn
- 2004-12-20 JP JP2006544554A patent/JP4901480B2/ja not_active Expired - Fee Related
- 2004-12-20 WO PCT/GB2004/005325 patent/WO2005061544A2/en active Application Filing
- 2004-12-20 AU AU2004303585A patent/AU2004303585B2/en not_active Ceased
- 2004-12-20 NZ NZ548013A patent/NZ548013A/en unknown
- 2004-12-20 KR KR1020067014806A patent/KR101150548B1/ko not_active IP Right Cessation
- 2004-12-20 PT PT04806128T patent/PT1711530E/pt unknown
- 2004-12-20 WO PCT/GB2004/005343 patent/WO2005061545A2/en not_active Application Discontinuation
-
2005
- 2005-07-06 US US11/177,648 patent/US7780964B2/en not_active Expired - Fee Related
-
2006
- 2006-06-08 IL IL176206A patent/IL176206A/en not_active IP Right Cessation
- 2006-06-12 IS IS8506A patent/IS2739B/is unknown
- 2006-06-13 NO NO20062767A patent/NO20062767L/no not_active Application Discontinuation
- 2006-07-10 MA MA29178A patent/MA28289A1/fr unknown
-
2007
- 2007-04-18 HK HK07104094.0A patent/HK1100144A1/xx not_active IP Right Cessation
-
2009
- 2009-10-01 HR HR20090527T patent/HRP20090527T1/xx unknown
- 2009-11-11 CY CY20091101175T patent/CY1110530T1/el unknown
-
2010
- 2010-08-23 US US12/861,205 patent/US20110054149A1/en not_active Abandoned
-
2013
- 2013-05-07 US US13/888,764 patent/US20140147435A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20090527T1 (en) | Nogo-a neutralising immunoglobulins for treatment of neurological diseases | |
| NZ604090A (en) | Human anti-b7rp1 neutralizing antibodies | |
| RS80704A (xx) | ANTI-αvβ6 ANTITELA | |
| SG151284A1 (en) | Antibodies against ccr5 and uses thereof | |
| NZ599196A (en) | Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors | |
| RS51829B (sr) | Ljudska antitela specifična za interleukin 15 (il-15) | |
| RS54393B1 (en) | HUMAN MONOCLONAL ANTIBODIES ON KINASE-1 SIMILAR TO ACTIVE RECEPTOR | |
| ATE420660T1 (de) | Antikörper gegen parath-hormon (pth) und ihre verwendungen | |
| RS54452B1 (en) | INGREDIENTS AND PROCEDURES FOR DIAGNOSIS AND TREATMENT OF CANCER | |
| CU23292B7 (es) | Anticuerpos monoclonales humanos de ctla-4 | |
| DE60333228D1 (de) | Gegen den tumor nekrose faktor gerichtete antikörper und deren verwendungen | |
| TW200634027A (en) | Antibodies directed to angiopoietin-2 and uses thereof | |
| GEP20074222B (en) | Antibodies to cd40 | |
| NZ611859A (en) | Antibody purification | |
| ATE476994T1 (de) | Antikörper gegen gpnmb und ihre verwendungen | |
| MY148409A (en) | Anti-mag antibodies | |
| MX2009001110A (es) | Anticuerpos monoclonales anti-il-6 y usos de los mismos. | |
| WO2007120693A3 (en) | Targeted binding agents directed to upar and uses thereof | |
| TW200716182A (en) | Antibodies directed to CD20 and uses thereof | |
| IN2009KN02655A (xx) | ||
| NZ594466A (en) | Human monoclonal antibodies to protein tyrosine kinase 7 (PTK7) and methods for using anti-PTK7 antibodies | |
| WO2008112004A3 (en) | ANTIBODIES DIRECTED TO αVβ6 AND USES THEREOF | |
| SG155883A1 (en) | Anti-cd3 antibodies and methods of use thereof | |
| BR0112086A (pt) | Anticorpos para mcp-1 humano | |
| HK1071898A1 (en) | Recombinant antibodies, and compositions and methods for making and using the same |